Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 2Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 290Prostatic Neoplasms 192Neoplasm Metastasis 154Multiple Myeloma 147Colorectal Neoplasms 123Lung Neoplasms 104Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 88Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 80Stomach Neoplasms 76Small Cell Lung Carcinoma 72Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 66Pain 66Uterine Cervical Neoplasms 64Carcinoma, Renal Cell 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Breakthrough Pain × Clear all
NCT00263575 2024-06-18

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Kyowa Kirin Co., Ltd.

Phase 3 Completed
139 enrolled 7 charts

Neoplasms, Pain, Breakthrough Pain

NCT01326689 2017-03-08

2246-004

Kyowa Kirin Co., Ltd.

Phase 3 Completed
42 enrolled

Cancer Pain, Breakthrough Pain

NCT01842893 2013-05-03

ETHYFYL

Ethypharm

Phase 3 Completed
91 enrolled

Neoplasms, Breakthrough Pain

NCT00236145 2013-01-29

Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡